GlaxoSmithKline plc (GSK)


NYSE - NYSE Real Time Price. Currency in USD
43.61+0.06 (+0.14%)
At close: 4:02 PM EDT

43.50 -0.11 (-0.25%)
After hours: 7:30 PM EDT

People also watch:
AZNNVSSNYLLYBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open43.54
Prev Close43.55
Bid43.62 x 1600
Ask43.63 x 7000
Day's Range43.39 - 43.70
52wk Range37.24 - 45.58
1y Target EstN/A
Market Cap105.99B
P/E Ratio (ttm)2,725.62
Beta1.00
Volume2,129,229
Avg Vol (3m)3,390,698
Dividend & Yield2.20 (5.06%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • TheStreet.com6 hours ago

    Gilead Sciences (GILD) Stock Down, Piper Jaffray 'Doubts' HIV Competitors

    Piper Jaffray said in a note Monday that Gilead Sciences (GILD) likely won't be impacted by GlaxoSmithKline's (GSK) potential new two-drug HIV regimen.

  • Barrons.com7 hours ago

    Gilead Sciences: Don't Expect Perfection

    As if Gilead Sciences (GILD) didn't have enough to worry about with competition in hepatitis C, now the Wall Street Journal is reporting that GlaxoSmithKline (GSK) is attempting to upend the HIV market too. Piper Jaffray's Joshua Schimmer and team don't seem to worried: We have had a number of incoming questions regarding the WSJ article highlighting a potential 2-drug HIV regimen based on GSK's dolutegravir. The costs of HIV resistance are very high, whereas the advantage of a 2-drug regimen over a 3-drug regimen (when both are 1-pill/once daily regimens anyways) is minimal.

  • Inside the FDA Ebola Edition: Frontrunners Merck & Co., Inc. (MRK), GlaxoSmithKline PLC (ADR) (GSK)
    Insider Monkey8 hours ago

    Inside the FDA Ebola Edition: Frontrunners Merck & Co., Inc. (MRK), GlaxoSmithKline PLC (ADR) (GSK)

    Introduction Back on May 12, 2015, the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee released a briefing document detailing the process for licensure of Ebola vaccines and the required demonstration of effectiveness. This Market Exclusive Inside the FDA report aims to go inside this briefing document, break it down, and […]